The sale is small relative to market cap (0.004%) and is part of a pre-arranged 10b5-1 plan, so it does not signal a change in insider view. Monitor for any unexpected deviation from the plan or a larger than usual sale outside the plan.
GILD drugs
GILD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $170.33entry
- T+1 · 14d ago −1.68%α −1.98% · $167.47
- T+5 · 8d ago −0.59%α −0.67% · $169.32
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Daniel O'Day filed a Form 144 notice of intent to sell 45,881 shares of Gilead Sciences common stock, with an approximate aggregate market value of $7.6 million based on the filing. The sale is planned for or around October 30, 2026, and includes shares acquired through stock option exercises and performance stock units. The filing is part of a pre-arranged 10b5-1 trading plan, which reduces the signal value of the insider sale signal.
Key Facts
- Insider: CEO Daniel Patrick O'Day (CEO)
- Shares to sell: 45,881 shares
- Approximate value: $7,598,352.41
- Plan date: October 30, 2026
- Shares acquired via exercise of stock options (15,881 shares) and performance stock units (30,000 shares)
- Sale is part of a 10b5-1 trading plan established on February 25, 2026
- Prior 10b5-1 sales in August, September, and October 2026 (15,000 shares each month
Financial Impact
$7.6 million sale relative to $197.4B market cap (0.004% of market cap)
Risk Factors
- Form 144 is only an intent to sell; the sale may not occur
- 10b5-1 plan reduces the signal value of the insider sale signal
- Prior 10b5-1 sales in August, September, and October 2026 (15,000 shares each month)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010512 |
| Document: 0001950047-26-010512-index.html | 0001950047-26-010512 |
| Document: 0001950047-26-010512.txt | 0001950047-26-010512 |
Track record
30 reports on GILD
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Viewing Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers